Ray Dalio's GILD Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 292,406 shares of Gilead Sciences, Inc. (GILD) worth $35.89 M, representing 0.13% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in GILD, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 295,800 shares. Largest reduction occurred in Q3 2024, reducing 583,702 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Gilead Sciences (GILD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Gilead Sciences (GILD) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2013 | +38,621 | New Buy | 38,621 | $75.09 |
| Q1 2014 | +209,100 | Add 541.42% | 247,721 | $70.86 |
| Q2 2014 | +102,100 | Add 41.22% | 349,821 | $82.91 |
| Q3 2014 | -108,300 | Reduce 30.96% | 241,521 | $106.45 |
| Q4 2014 | +295,800 | Add 122.47% | 537,321 | $94.26 |
| Q1 2015 | -512,100 | Reduce 95.31% | 25,221 | $98.13 |
| Q2 2015 | +56,500 | Add 224.02% | 81,721 | $117.08 |
| Q3 2015 | +140,400 | Add 171.80% | 222,121 | $98.19 |
| Q4 2015 | -4,000 | Reduce 1.80% | 218,121 | $101.19 |
| Q1 2016 | +31,700 | Add 14.53% | 249,821 | $91.86 |
| Q2 2016 | +124,851 | Add 49.98% | 374,672 | $83.42 |
| Q3 2016 | -59,400 | Reduce 15.85% | 315,272 | $79.12 |
| Q4 2016 | -235,000 | Reduce 74.54% | 80,272 | $71.61 |
| Q1 2017 | -80,272 | Sold Out | 0 | $0.00 |
| Q2 2018 | +52,316 | New Buy | 52,316 | $70.84 |
| Q3 2018 | -17,666 | Reduce 33.77% | 34,650 | $77.20 |
| Q4 2018 | +124,662 | Add 359.77% | 159,312 | $62.55 |
| Q1 2019 | -34,684 | Reduce 21.77% | 124,628 | $65.01 |
| Q2 2019 | -32,739 | Reduce 26.27% | 91,889 | $67.56 |
| Q3 2019 | +30,829 | Add 33.55% | 122,718 | $63.38 |
| Q4 2019 | -122,718 | Sold Out | 0 | $0.00 |
| Q4 2020 | +50,600 | New Buy | 50,600 | $58.26 |
| Q1 2021 | +10,992 | Add 21.72% | 61,592 | $64.64 |
| Q2 2021 | +65,118 | Add 105.72% | 126,710 | $68.86 |
| Q3 2021 | -82,091 | Reduce 64.79% | 44,619 | $69.86 |
| Q4 2021 | -1,481 | Reduce 3.32% | 43,138 | $72.60 |
| Q1 2022 | +278,934 | Add 646.61% | 322,072 | $59.45 |
| Q2 2022 | +263,412 | Add 81.79% | 585,484 | $61.81 |
| Q3 2022 | -298,584 | Reduce 51.00% | 286,900 | $61.69 |
| Q4 2022 | -8,392 | Reduce 2.93% | 278,508 | $85.85 |
| Q1 2023 | +218,141 | Add 78.32% | 496,649 | $82.97 |
| Q2 2023 | +249,061 | Add 50.15% | 745,710 | $77.07 |
| Q3 2023 | -13,199 | Reduce 1.77% | 732,511 | $74.94 |
| Q4 2023 | +75,408 | Add 10.29% | 807,919 | $81.01 |
| Q1 2024 | +203,849 | Add 25.23% | 1.01 M | $73.25 |
| Q2 2024 | -221,124 | Reduce 21.86% | 790,644 | $68.61 |
| Q3 2024 | -583,702 | Reduce 73.83% | 206,942 | $83.84 |
| Q4 2024 | +253,994 | Add 122.74% | 460,936 | $92.37 |
| Q1 2025 | +42,017 | Add 9.12% | 502,953 | $112.05 |
| Q2 2025 | +163,347 | Add 32.48% | 666,300 | $110.87 |
| Q3 2025 | -280,936 | Reduce 42.16% | 385,364 | $111.00 |
| Q4 2025 | -92,958 | Reduce 24.12% | 292,406 | $122.74 |
Ray Dalio's Gilead Sciences Investment FAQs
Ray Dalio first purchased Gilead Sciences, Inc. (GILD) in Q4 2013, acquiring 38,621 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Gilead Sciences, Inc. (GILD) for 42 quarters since Q4 2013.
Ray Dalio's largest addition to Gilead Sciences, Inc. (GILD) was in Q4 2014, adding 537,321 shares worth $50.65 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 292,406 shares of Gilead Sciences, Inc. (GILD), valued at approximately $35.89 M.
As of the Q4 2025 filing, Gilead Sciences, Inc. (GILD) represents approximately 0.13% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Gilead Sciences, Inc. (GILD) was 1,011,768 shares, as reported at the end of Q1 2024.